Understanding the drivers behind disease with the 100,000 Genomes Project
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
Can we target AML with CAR T-cells?
Can BiTEs and CAR T-cells be used to treat MCL?